DGAP-News: UMS United Medical Systems International AG / Key word(s): Alliance New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement with IceCure 18.05.2011 / 09:54 --------------------------------------------------------------------- New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement with IceCure Hamburg, May 18, 2011 - UMS United Medical Systems International AG (UMS/ ISIN DE0005493654) has entered into an exclusive agreement in the United States with IceCure Medical, an innovative provider of medical technology from Israel, for the mobile deployment of IceCure's medical product IceSense3 for cryoablation. IceSense3 is approved by the Food and Drug Administration (FDA) in the United States for the treatment of benign tumors in the female breast (fibroadenoma). The partnership with IceCure adds an additional treatment field to UMS's breast care segment. Cryoablation or cryotherapy is a non-invasive procedure to remove benign tumors in the female breast. In the United States alone around 500,000 of these tumors are surgically removed every year. UMS plans to build up the U.S. market for mobile services using IceSense3 in the next six to twelve months. By offering daily mobile cryoablation systems in combination with modern ultrasound technology, UMS is expanding its services to physicians to include another full-service package on attractive conditions. About UMS AG UMS International AG is a provider of innovative healthcare delivery concepts in the growth segment of high-tech medicine. UMS pioneered the mobile deployment of high-class medical systems and markets a comprehensive range of full-service solutions for hospitals and specialists. The forward-looking concepts include complete services for the customer, covering everything from system management to the provision of trained application specialists. The UMS Group currently has around 200 employees worldwide and serves over 600 customers. Contact Wiebke Budwasch, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail: investor@umsag.com End of Corporate News --------------------------------------------------------------------- 18.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: UMS United Medical Systems International AG Borsteler Chaussee 53 22453 Hamburg Deutschland Phone: +49 (0)40 - 500 177 - 00 Fax: +49 (0)40 - 500 177 - 77 E-mail: investor@umsag.com Internet: www.umsag.com ISIN: DE0005493654 WKN: 549365 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 125083 18.05.2011
DGAP-News: New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement with IceCure
| Source: EQS Group AG